Careium - Short-term Pain
2022-03-04 10:00:00
Redeye takes a slightly more conservative stance on Careium after the first report as a standalone company. We still believe the company is well-positioned for future growth but think it will take longer than expected with lower profitability in the meantime.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/